FDA’s Megha Kaushal ASGCT Talk: PFDD, Patient Voices, Decision-Making

Key Takeaways

• FDA emphasizes early patient input in CGT trial design
• Patient‑Focused Drug Development (PFDD) now central to FDA strategy
• Family-reported outcomes can guide post‑unblinding analysis
• Regulatory integration faces data harmonization challenges
• Leadership turnover may affect PFDD consistency

Pulse Analysis

The FDA is sharpening its focus on patient‑centered drug development, a shift that was underscored by Acting Deputy Director Megha Kaushal’s presentation at the 2026 American Society of Gene & Cell Therapy (ASGCT) meeting in Boston. Kaushal framed the agency’s Patient‑Focused Drug Development (PFDD) initiative as a guiding principle for emerging cell and gene therapies, urging sponsors to embed patient and caregiver insights from the earliest stages of protocol design. By aligning regulatory expectations with lived‑experience data, the FDA hopes to accelerate trial relevance, improve endpoint selection, and ultimately bring transformative therapies to patients faster.

Integrating family‑reported outcomes into formal regulatory submissions, however, presents practical hurdles. Kaushal highlighted scenarios where a small pediatric trial may show no statistically significant efficacy, yet a subset of families observes meaningful clinical improvement. Determining whether such anecdotal signals correspond to the investigational product requires careful post‑unblinding analysis and robust data‑linkage mechanisms. The FDA is exploring structured patient‑reported outcome measures and real‑world evidence platforms to reconcile qualitative insights with quantitative endpoints, but standardizing collection, validation, and privacy safeguards remains an ongoing challenge for sponsors and regulators alike.

The heightened emphasis on PFDD arrives amid a turbulent period for the Center for Biologics Evaluation and Research (CBER), marked by successive leadership changes that have slowed decision‑making on complex biologics. Industry observers warn that inconsistent guidance could dilute the impact of patient‑centric policies, potentially delaying approvals for high‑risk cell and gene products. Nonetheless, the FDA’s public commitment to “patients at the heart of everything” signals a long‑term strategic pivot. Companies that proactively embed patient voices into trial design, data collection, and post‑marketing plans are likely to gain regulatory goodwill and a competitive edge as the agency refines its PFDD framework.